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SHORT COMMUNICATION
Antitumour responses to flavone-8-acetic acid and
5,6-dimethylxanthenone-4-acetic acid in immune deficient mice
L.-M. Ching, W.R. Joseph & B.C. Baguley
Cancer Research Laboratory, Auckland University Medical School, Auckland, New Zealand.
Flavone-8-acetic acid (FAA) is a synthetic flavonoid with
impressive preclinical activity but no clinical activity as a
single agent (Kerr & Kaye, 1989). 5,6-MeXAA is a fused
tricyclic analogue of FAA developed in this laboratory (Rew-
castle et al., 1991). It has improved antitumour activity and
12-fold higher dose potency when compared to FAA, and is
a candidate drug for clinical trial. FAA and 5,6-MeXAA
share many properties with endotoxin: they induce the syn-
thesis of tumour necrosis factor (TNF) (North & Havell,
1988; Mace et al., 1990) and stimulate the formation of nitric
oxide, both in vitro (Drapier et al., 1988; Thomsen et al.,
1990) and in vivo (Stuehr & Marletta, 1985; Thomsen et al.,
1991). There are two main facets to the action of these
agents. Firstly, by inducing TNF they promote the cessation
of tumour blood flow and cell death by tumour ischaemia
(Evelhoch et al., 1988; North & Havell, 1988; Zwi et al.,
1989; Mahadevan et al., 1990). Secondly, macrophage-
(Stewart et al., 1988) or lymphocyte (Berendt et al., 1978)
mediated cytotoxicity leads to further killing of residual
tumour cells. T-lymphocyte mediated immunity has been
implicated in the action of both endotoxin (Berendt et al.,
1978) and of FAA (Pratesi et al., 1990; Bibby et al., 1991).
We report here that FAA and 5,6-MeXAA induce growth
delays and cures of the Colon 38 adenocarcinoma in T-cell
depleted mice, and can therefore function effectively, at least
against some tumours, by T-cell independent mechanisms.
As demonstrated previously (Rewcastle et al., 1991;
Thomsen et al., 1991), 5,6-MeXAA and FAA, when admini-
stered in a single dose schedule to BDF, (C57B1/6J x DBA/
2J) hybrid mice with palpable subcutaneous Colon 38
tumours, induced substantial growth delays and cures (Table
I). In order to investigate the role of T-cells in this response,
nude (athymic) and T-cell deficient thymectomised (T x B)
mice were subjected to similar treatment. C57B1/6 nu/nu mice
(obtained from Mr V. Jansen, Auckland Medical School)
and BDF, mice were bred under conditions of constant
temperature and humidity, using sterile bedding and food
and following institutional animal ethical guidelines. T x B
mice were prepared by thymectomising BDF, mice at 6
weeks of age and irradiating (9.5 Gy) 1 week later with a
'"Cobalt source. Syngeneic bone marrow cells (2 x 106) were
injected intravenously and mice were used for experiments 6
weeks after bone marrow reconstitution. At the end of each
experiment, all mice were examined for complete removal of
thymic glands. T-cell deficiency was checked by culturing
spleen cells (106 cellsml-') from individual mice with con-
canavalin A (2pgml-'; Sigma) and measuring tritiated
thymidine uptake after 3 days. T x B mice incorporated less
than 5% of the radioactivity of that of euthymic controls.
Colon 38 fragments were implanted subcutaneously. Mice
bearing tumours 4-8 mm in diameter were selected for each
experiment and randomised with respect to tumour size into
treatment and control groups (at least five mice per group).
FAA (obtained from the National Cancer Institute, USA)
and the sodium salt of 5,6-MeXAA (synthesised in this
laboratory) were dissolved in 5% (w/v) sodium bicarbonate,
protected from light (Rewcastle et al., 1990), and admini-
stered as a single i.p. (intraperitoneal) dose to mice in treat-
ment groups. Tumours were measured thereafter three times
weekly with callipers and tumour volumes calculated as
0.52a2b, where a and b were the minor and major axes of the
tumour. The arithmetic means (used in order to include those
which had completely regressed) and standard errors of the
tumour volumes were determined at each time point and
expressed as fractions of the initial mean tumour volume.
5,6-MeXAA and FAA were administered at two different
doses to euthymic, T x B and athymic nude mice which had
been previously implanted with Colon 38 tumours (Table I).
Drug toxicity, when present, occurred within 24 h of
administration and was more frequent in T x B mice than in
nude or euthymic mice. 5,6-MeXAA and FAA induced
growth delays in all three groups of mice, although tumour
cure rates for 5,6-MeXAA in T x B and athymic mice were
lower than in euthymic mice (Table I). Mean tumour
volumes in both FAA and 5,6-MeXAA treated groups were
significantly lower from day 4 after treatment in T x B mice
(Figure 1) and from day 3 after treatment in athymic mice
(Figure 2). Within the limits imposed by the numbers of
animals used, there was no relationship between initial
tumour size and either toxicity or cure rate.
To evaluate the role of tumour haemorrhagic necrosis in
tumour response, some tumours were removed 24 h after
drug treatment, fixed, embedded, sectioned and stained with
haematoxylin and eosin. A grid marked at 0.4 mm intervals
was placed over the slide and the intersections were scored as
either undamaged or necrotic as previously described (Bagu-
ley et al., 1989). The results were similar for all three groups
of mice and confirmed the conclusion, obtained previously
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Figure 1 Colon 38 tumour growth delays in groups of T x B
mice treated (day 0) with FAA (300 mg kg-', eight mice; 0) or
5,6-MeXAA (27.5 mg kg-', seven mice; A) or untreated (five
mice; 0).
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Table I Antitumour responses in T-cell deficient mice
Dose Growth delay Toxic deaths
Host Drug (mgkg-') % Necrosis (days) Cures (24 h)
Euthymica FAA 330 100 17 3/6 0/6
5,6-MeXAA 30 100 20 12/15 0/15
T x B FAA 330 88 9 0/6 1/6
300 100 10 4/10 2/10
5,6-MeXAA 30 70 17 1/8 5/8
27.5 100 15 1/7 0/7
Athymic FAA 330 61 8 2/5 0/5
300 83 6 0/5 2/5
5,6-MeXAA 30 65 14 2/5 1/5
27.5 72 4 0/9 2/9
aData averaged from several experiments (Rewcastle et al., 1991; Thomsen et al., 1991).
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Figure 2 Colon 38 tumour growth delays in groups of nude mice
treated (day 0) with FAA (330 mg kg-', five mice; 0) or 5,6-
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Figure 3 Growth of second tumour implants in cured mice.
Euthymic (three mice; A) or T x B (three mice; 0) which had
been cured for 140 days of Colon 38 after treatment with FAA or
5,6-MeXAA were reimplanted with Colon 38 tumours (day 0)
and tumour volumes (pi) were compared with those in naive
euthymic control mice (five mice; 0).
tumour necrosis was necessary but not sufficient for signifi-
cant tumour growth delay.
To determine whether immunity had been generated by the
growth of the primary tumour, mice which had previously
been cured by treatment with either FAA or 5,6-MeXAA
were reimplanted after 140 days with a second Colon 38
tumour. Secondary implants were found to grow in T x B
mice at the same rates at in naive euthymic control mice
(Figure 3). Secondary Colon 38 implants also grew in
previously cured euthymic hosts. Although a slightly longer
time was required for tumours to become palpable, the
tumour volumes were not significantly smaller than those in
the control mice (Figure 3). Lewis lung tumours (Finlay et
al., 1988) were found to grow equally well in naive control
mice or euthymic or T x B mice which had previously been
cured of a Colon 38 tumour (data not shown).
The results (Table I) contrast with those of other reports
(Pratesi et al., 1990; Bibby et al., 1991) where inhibition of
tumour growth by FAA was observed in euthymic hosts
only, but emphasise the heterogeneity of host antitumour
response mechanisms. Although differing drug administration
schedules may have played a role, the most likely explanation
for this discordance is that T-cell dependent cytotoxicity is
less important in the response of Colon 38 tumours than it is
in the other tumours reported. North and co-workers have
shown that different murine tumour models vary in their
immunogenicity and in their effects on the host's immunity
(Berendt et al., 1978). Immunogenic tumours induce the
generation of long-term T-cell immunity specific to the
tumour, while others induced suppression of initially gener-
ated immunity, and yet are non-immunogenic with no effect
on the immunity of the host. The longer lag period required
before a second Colon 38 implant became palpable in pre-
viously cured mice, together with the observation that there
were more complete regressions of the primary tumours in
euthymic hosts than in T-cell deficient mice, suggest that
Colon 38 may be weakly immunogenic.
In summary, we have demonstrated haemorrhagic necrosis,
growth delay and complete regression of Colon 38 tumours
which appear to be largely independent of T-cell activity.
Other mechanisms of potential cytotoxicity, including the
induction ofcells in the natural killer lineage (Hornung et al.,
1988), and macrophage-mediated killing via the production
of TNF or nitric oxide (Ching & Baguley, 1988; Thomsen et
al., 1990), may thus operate in concert with tumour ischae-
mia (Zwi et al., 1989) to cause tumour regression, with the
contributions of each varying according to the tumour.
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